GLG News by Pediatricians in Private Practice (US)

The recent decision of the Bush Administration to curtail the scope of the Children's Health insureance plan will have three main outcomes: 1) An increase in the number of uninsured and under-insured children (imagine a family of four earning less than $60K in a metropolitan area, not receiving health...

Levocetirizine has been approved by the FDA for treatment of allergic rhinitis and other allergic manifestations (e.g., urticaria), which means that there is yet another anti-histamine on the market with similar efficacy as already-approved anti-histamines, and yet another drug of minor (if any) marginal...

The new Medicare guidelines -- which restrict reimbursement for cases in which "preventable" complications occur -- does not distinguish between what is a truly "preventable error" and what is a more or less accepted rate of complication for somewhat risky procedures.  The fact that doctors and...

I have long been concerned about this issue - not only for Hep B, but moreover for Varicella, and measles, etc.  It is my prediction that, before the end of my medical career, immunizations will take a greater part in the Family Medicine/Internal Medicine practices, and people will need to receive...

The continued trend of concierge medicine will serve to further segregate and fragement our over burdened health care system.  It remains to be seen then long effect of this practice model.

This seem dubious at best -- drinking coffee can prevent cancer.            

Not surprisingly the BLues are cutting reimbursement to physicians yet their rates continue to rise and their employee compensation continues to rise. It is time for employeers to demand that the highly paid executives of the Blues justify their excessive salaries and efficiencies of the Blues be fixed....

Medimmunes novel mAb to the Il5 receptor represents a novel way to decrease eosinophils. While this represents a potentially important therapeutic modality in asthma mangement, previous attempts with mepolizumab ( anti IL 5 ) proved disaapointing. Mepolizumab like medimmune's new agent was able to decrease...

Symbicort is AstraZeneca's answer to Advair, presently the number one combination ICS/LABA in the U.S. for treating moderate to severe asthma. Symbicort will not, however, have an indication for quick relief of bronchospasm as it does in many European countries. Nevertheless, Symbicort appears to be...

Yet another antihistamine in a saturated market with less expensive alternatives. Antihistamines are not the drug of choice for significant allergic rhinitis